We are analyzing https://link.springer.com/article/10.1007/s10555-013-9468-y.

Title:
Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets | Cancer and Metastasis Reviews
Description:
Neuroendocrine tumors (NETs) represent a heterogeneous group of diseases with varied natural history and prognosis depending upon the organ of origin and grade of aggressiveness. The most widely used biomarker to determine disease burden and monitor response to treatment is chromogranin A (CgA), but it is far from being the optimal predictive and prognostic biomarker in NETs. Biological understanding and derived treatment options for NETs have changed markedly in recent years. Over the last decade, the genomic landscape of these tumors has been extensively investigated. This has resulted in the discovery of mutations and expression anomalies in genes and pathways such as the PI3K/Akt/mTOR, DAXX/ATRX, and MEN1, which are promising predictive and prognostic biomarkers and future candidates for targeted therapies. Additionally, the study of tumor stroma and environment are one of the most promising fields for discovery of potential new targets and biomarkers.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,643,328 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

pubmed, article, google, scholar, tumors, cas, neuroendocrine, journal, cancer, clinical, oncology, central, pancreatic, research, biomarkers, study, patients, tumor, medicine, molecular, pietras, pathology, advanced, treatment, expression, yao, everolimus, department, privacy, cookies, content, metastasis, capdevila, casanovas, chromogranin, endocrine, university, science, therapy, nature, england, survival, phase, analysis, publish, search, pathways, targets, scarpa, nets,

Topics {✒️}

month download article/chapter multitargeted chemo-switch regimen pegylated interferon alpha-2b metastatic renal-cell carcinoma ajcc/uicc tnm classifications octreotide long-acting repeatable pancreatic beta-cell tumors intermediate-grade neuroendocrine tumors full article pdf de wilde endocrine-related cancer [universidad de sevilla privacy choices/manage cookies pancreatic endocrine tumors metastasis reviews aims pancreatic neuroendocrine tumors pancreatic neuroendocrine carcinogenesis article cancer advanced neuroendocrine tumors gastroenteropancreatic neuroendocrine tumors unresectable neuroendocrine tumors hebron university hospital phase ii trial find pericyte biomarkers instituto carlos iii clinical cancer research consensus proposal including endothelial-pericyte interactions phase ii study advanced pnet treated molecular biology european economic area scope submit manuscript varied natural history determine disease burden pi3k/akt/mtor world health organization profiling mtor pathway akt-mtor pathway global microrna profiling neuron-specific enolase increased local invasion paez-ribes institutcatalàd’oncología-idibell experimental cell research anti-angiogenic therapy conditions privacy policy specific blood biomarkers related subjects future therapeutic approaches

Questions {❓}

Chromogranin A: is it a useful marker of neuroendocrine tumors?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets
         description:Neuroendocrine tumors (NETs) represent a heterogeneous group of diseases with varied natural history and prognosis depending upon the organ of origin and grade of aggressiveness. The most widely used biomarker to determine disease burden and monitor response to treatment is chromogranin A (CgA), but it is far from being the optimal predictive and prognostic biomarker in NETs. Biological understanding and derived treatment options for NETs have changed markedly in recent years. Over the last decade, the genomic landscape of these tumors has been extensively investigated. This has resulted in the discovery of mutations and expression anomalies in genes and pathways such as the PI3K/Akt/mTOR, DAXX/ATRX, and MEN1, which are promising predictive and prognostic biomarkers and future candidates for targeted therapies. Additionally, the study of tumor stroma and environment are one of the most promising fields for discovery of potential new targets and biomarkers.
         datePublished:2013-12-28T00:00:00Z
         dateModified:2013-12-28T00:00:00Z
         pageStart:345
         pageEnd:351
         sameAs:https://doi.org/10.1007/s10555-013-9468-y
         keywords:
            Neuroendocrine tumors
            Biomarker
            Chromogranin A
            Cancer Research
            Oncology
            Biomedicine
            general
         image:
         isPartOf:
            name:Cancer and Metastasis Reviews
            issn:
               1573-7233
               0167-7659
            volumeNumber:33
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:J. Capdevila
               affiliation:
                     name:Spanish Ministry of Science and Innovation
                     address:
                        name:Department of Medical Oncology, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Center affiliated to the Red Temática de Investigación Cooperativa en Cancer (RTICC), Instituto Carlos III, Spanish Ministry of Science and Innovation, Barcelona, Spain
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:A. Meeker
               affiliation:
                     name:Johns Hopkins University School of Medicine
                     address:
                        name:Department of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:R. García-Carbonero
               affiliation:
                     name:Spanish Ministry of Science and Innovation
                     address:
                        name:Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS) [Universidad de Sevilla, CSIC, HUVR], Center affiliated to the Red Temática de Investigación Cooperativa en Cancer (RTICC), Instituto Carlos III, Spanish Ministry of Science and Innovation, Sevilla, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:K. Pietras
               affiliation:
                     name:Lund University
                     address:
                        name:Department of Laboratory Medicine, Center for Molecular Pathology, Lund University, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. Astudillo
               affiliation:
                     name:Hospital Universitario Central de Asturias
                     address:
                        name:Department of Pathology, Hospital Universitario Central de Asturias, Asturias, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:O. Casanovas
               affiliation:
                     name:Spanish Ministry of Science and Innovation
                     address:
                        name:Laboratori de Recerca Traslacional, InstitutCatalàd’Oncología-IDIBELL, L’Hospitalet, Center affiliated to the Red Temática de Investigación Cooperativa en Cancer (RTICC), Instituto Carlos III, Spanish Ministry of Science and Innovation, Barcelona, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. Scarpa
               affiliation:
                     name:University of Verona
                     address:
                        name:ARC-NET Research Centre and Department of Pathology and Diagnostics, University of Verona, Verona, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets
      description:Neuroendocrine tumors (NETs) represent a heterogeneous group of diseases with varied natural history and prognosis depending upon the organ of origin and grade of aggressiveness. The most widely used biomarker to determine disease burden and monitor response to treatment is chromogranin A (CgA), but it is far from being the optimal predictive and prognostic biomarker in NETs. Biological understanding and derived treatment options for NETs have changed markedly in recent years. Over the last decade, the genomic landscape of these tumors has been extensively investigated. This has resulted in the discovery of mutations and expression anomalies in genes and pathways such as the PI3K/Akt/mTOR, DAXX/ATRX, and MEN1, which are promising predictive and prognostic biomarkers and future candidates for targeted therapies. Additionally, the study of tumor stroma and environment are one of the most promising fields for discovery of potential new targets and biomarkers.
      datePublished:2013-12-28T00:00:00Z
      dateModified:2013-12-28T00:00:00Z
      pageStart:345
      pageEnd:351
      sameAs:https://doi.org/10.1007/s10555-013-9468-y
      keywords:
         Neuroendocrine tumors
         Biomarker
         Chromogranin A
         Cancer Research
         Oncology
         Biomedicine
         general
      image:
      isPartOf:
         name:Cancer and Metastasis Reviews
         issn:
            1573-7233
            0167-7659
         volumeNumber:33
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:J. Capdevila
            affiliation:
                  name:Spanish Ministry of Science and Innovation
                  address:
                     name:Department of Medical Oncology, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Center affiliated to the Red Temática de Investigación Cooperativa en Cancer (RTICC), Instituto Carlos III, Spanish Ministry of Science and Innovation, Barcelona, Spain
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:A. Meeker
            affiliation:
                  name:Johns Hopkins University School of Medicine
                  address:
                     name:Department of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:R. García-Carbonero
            affiliation:
                  name:Spanish Ministry of Science and Innovation
                  address:
                     name:Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS) [Universidad de Sevilla, CSIC, HUVR], Center affiliated to the Red Temática de Investigación Cooperativa en Cancer (RTICC), Instituto Carlos III, Spanish Ministry of Science and Innovation, Sevilla, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:K. Pietras
            affiliation:
                  name:Lund University
                  address:
                     name:Department of Laboratory Medicine, Center for Molecular Pathology, Lund University, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. Astudillo
            affiliation:
                  name:Hospital Universitario Central de Asturias
                  address:
                     name:Department of Pathology, Hospital Universitario Central de Asturias, Asturias, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:O. Casanovas
            affiliation:
                  name:Spanish Ministry of Science and Innovation
                  address:
                     name:Laboratori de Recerca Traslacional, InstitutCatalàd’Oncología-IDIBELL, L’Hospitalet, Center affiliated to the Red Temática de Investigación Cooperativa en Cancer (RTICC), Instituto Carlos III, Spanish Ministry of Science and Innovation, Barcelona, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. Scarpa
            affiliation:
                  name:University of Verona
                  address:
                     name:ARC-NET Research Centre and Department of Pathology and Diagnostics, University of Verona, Verona, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer and Metastasis Reviews
      issn:
         1573-7233
         0167-7659
      volumeNumber:33
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Spanish Ministry of Science and Innovation
      address:
         name:Department of Medical Oncology, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Center affiliated to the Red Temática de Investigación Cooperativa en Cancer (RTICC), Instituto Carlos III, Spanish Ministry of Science and Innovation, Barcelona, Spain
         type:PostalAddress
      name:Johns Hopkins University School of Medicine
      address:
         name:Department of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, USA
         type:PostalAddress
      name:Spanish Ministry of Science and Innovation
      address:
         name:Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS) [Universidad de Sevilla, CSIC, HUVR], Center affiliated to the Red Temática de Investigación Cooperativa en Cancer (RTICC), Instituto Carlos III, Spanish Ministry of Science and Innovation, Sevilla, Spain
         type:PostalAddress
      name:Lund University
      address:
         name:Department of Laboratory Medicine, Center for Molecular Pathology, Lund University, Lund, Sweden
         type:PostalAddress
      name:Hospital Universitario Central de Asturias
      address:
         name:Department of Pathology, Hospital Universitario Central de Asturias, Asturias, Spain
         type:PostalAddress
      name:Spanish Ministry of Science and Innovation
      address:
         name:Laboratori de Recerca Traslacional, InstitutCatalàd’Oncología-IDIBELL, L’Hospitalet, Center affiliated to the Red Temática de Investigación Cooperativa en Cancer (RTICC), Instituto Carlos III, Spanish Ministry of Science and Innovation, Barcelona, Spain
         type:PostalAddress
      name:University of Verona
      address:
         name:ARC-NET Research Centre and Department of Pathology and Diagnostics, University of Verona, Verona, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:J. Capdevila
      affiliation:
            name:Spanish Ministry of Science and Innovation
            address:
               name:Department of Medical Oncology, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Center affiliated to the Red Temática de Investigación Cooperativa en Cancer (RTICC), Instituto Carlos III, Spanish Ministry of Science and Innovation, Barcelona, Spain
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:A. Meeker
      affiliation:
            name:Johns Hopkins University School of Medicine
            address:
               name:Department of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, USA
               type:PostalAddress
            type:Organization
      name:R. García-Carbonero
      affiliation:
            name:Spanish Ministry of Science and Innovation
            address:
               name:Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS) [Universidad de Sevilla, CSIC, HUVR], Center affiliated to the Red Temática de Investigación Cooperativa en Cancer (RTICC), Instituto Carlos III, Spanish Ministry of Science and Innovation, Sevilla, Spain
               type:PostalAddress
            type:Organization
      name:K. Pietras
      affiliation:
            name:Lund University
            address:
               name:Department of Laboratory Medicine, Center for Molecular Pathology, Lund University, Lund, Sweden
               type:PostalAddress
            type:Organization
      name:A. Astudillo
      affiliation:
            name:Hospital Universitario Central de Asturias
            address:
               name:Department of Pathology, Hospital Universitario Central de Asturias, Asturias, Spain
               type:PostalAddress
            type:Organization
      name:O. Casanovas
      affiliation:
            name:Spanish Ministry of Science and Innovation
            address:
               name:Laboratori de Recerca Traslacional, InstitutCatalàd’Oncología-IDIBELL, L’Hospitalet, Center affiliated to the Red Temática de Investigación Cooperativa en Cancer (RTICC), Instituto Carlos III, Spanish Ministry of Science and Innovation, Barcelona, Spain
               type:PostalAddress
            type:Organization
      name:A. Scarpa
      affiliation:
            name:University of Verona
            address:
               name:ARC-NET Research Centre and Department of Pathology and Diagnostics, University of Verona, Verona, Italy
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Medical Oncology, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Center affiliated to the Red Temática de Investigación Cooperativa en Cancer (RTICC), Instituto Carlos III, Spanish Ministry of Science and Innovation, Barcelona, Spain
      name:Department of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, USA
      name:Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS) [Universidad de Sevilla, CSIC, HUVR], Center affiliated to the Red Temática de Investigación Cooperativa en Cancer (RTICC), Instituto Carlos III, Spanish Ministry of Science and Innovation, Sevilla, Spain
      name:Department of Laboratory Medicine, Center for Molecular Pathology, Lund University, Lund, Sweden
      name:Department of Pathology, Hospital Universitario Central de Asturias, Asturias, Spain
      name:Laboratori de Recerca Traslacional, InstitutCatalàd’Oncología-IDIBELL, L’Hospitalet, Center affiliated to the Red Temática de Investigación Cooperativa en Cancer (RTICC), Instituto Carlos III, Spanish Ministry of Science and Innovation, Barcelona, Spain
      name:ARC-NET Research Centre and Department of Pathology and Diagnostics, University of Verona, Verona, Italy
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(192)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.37s.

LINK . SPRINGER . COM {}